Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Publication
, Journal Article
Packer, M; Claggett, B; Lefkowitz, MP; McMurray, JJV; Rouleau, JL; Solomon, SD; Zile, MR
Published in: The Lancet Diabetes & Endocrinology
July 2018
Duke Scholars
Published In
The Lancet Diabetes & Endocrinology
DOI
ISSN
2213-8587
Publication Date
July 2018
Volume
6
Issue
7
Start / End Page
547 / 554
Publisher
Elsevier BV
Related Subject Headings
- 3205 Medical biochemistry and metabolomics
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Packer, M., Claggett, B., Lefkowitz, M. P., McMurray, J. J. V., Rouleau, J. L., Solomon, S. D., & Zile, M. R. (2018). Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. The Lancet Diabetes & Endocrinology, 6(7), 547–554. https://doi.org/10.1016/s2213-8587(18)30100-1
Packer, Milton, Brian Claggett, Martin P. Lefkowitz, John J. V. McMurray, Jean L. Rouleau, Scott D. Solomon, and Michael R. Zile. “Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.” The Lancet Diabetes & Endocrinology 6, no. 7 (July 2018): 547–54. https://doi.org/10.1016/s2213-8587(18)30100-1.
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. The Lancet Diabetes & Endocrinology. 2018 Jul;6(7):547–54.
Packer, Milton, et al. “Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.” The Lancet Diabetes & Endocrinology, vol. 6, no. 7, Elsevier BV, July 2018, pp. 547–54. Crossref, doi:10.1016/s2213-8587(18)30100-1.
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. The Lancet Diabetes & Endocrinology. Elsevier BV; 2018 Jul;6(7):547–554.
Published In
The Lancet Diabetes & Endocrinology
DOI
ISSN
2213-8587
Publication Date
July 2018
Volume
6
Issue
7
Start / End Page
547 / 554
Publisher
Elsevier BV
Related Subject Headings
- 3205 Medical biochemistry and metabolomics
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics